Cargando…

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review

Modifications in the microbiota caused by environmental and genetic reasons can unbalance the intestinal homeostasis, deregulating the host’s metabolism and immune system, intensifying the risk factors for the development and aggravation of non-alcoholic fat liver disease (NAFLD). The use of probiot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carpi, Rodrigo Zamignan, Barbalho, Sandra M., Sloan, Katia Portero, Laurindo, Lucas Fornari, Gonzaga, Heron Fernando, Grippa, Paulo Cesar, Zutin, Tereza L. Menegucci, Girio, Raul J. S., Repetti, Cláudia Sampaio Fonseca, Detregiachi, Cláudia Rucco Penteado, Bueno, Patrícia C. Santos, Mazuqueli Pereira, Eliana de Souza Bastos, Goulart, Ricardo de Alvares, Haber, Jesselina Francisco dos Santos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369010/ https://www.ncbi.nlm.nih.gov/pubmed/35955942 http://dx.doi.org/10.3390/ijms23158805

Ejemplares similares

The Influence of Body Fat and Lean Mass on HbA1c and Lipid Profile in Children and Adolescents with Type 1 Diabetes Mellitus
por: Menegucci, Thais, et al.
Publicado: (2023)

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
por: dos Santos, João Paulo Margiotti, et al.
Publicado: (2022)

Organokines in Rheumatoid Arthritis: A Critical Review
por: Laurindo, Lucas Fornari, et al.
Publicado: (2022)

Organokines in COVID-19: A Systematic Review
por: Barbalho, Sandra Maria, et al.
Publicado: (2023)

Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review
por: Mellen, Rodrigo Haber, et al.
Publicado: (2023)

The Effects of Curcumin on Diabetes Mellitus: A Systematic Review
por: Marton, Ledyane Taynara, et al.
Publicado: (2021)

Ginkgo biloba in the Aging Process: A Narrative Review
por: Barbalho, Sandra Maria, et al.
Publicado: (2022)

Design and validation of equations for weight estimation in adolescents
por: Coracini, Daniel Meyer, et al.
Publicado: (2023)

Effects of Medicinal Plants and Phytochemicals in Nrf2 Pathways during Inflammatory Bowel Diseases and Related Colorectal Cancer: A Comprehensive Review
por: Laurindo, Lucas Fornari, et al.
Publicado: (2023)

Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH)
por: Cortez-Pinto, Helena, et al.
Publicado: (2016)

Radiological and Functional Pulmonary Evolution in Post-COVID-19 Patients: An Observational Study
por: Cavallari Strozze Catharin, Virgínia Maria, et al.
Publicado: (2023)

Association of Metabolic Syndrome and Hyperferritinemia in Patients at Cardiovascular Risk
por: Tofano, Ricardo José, et al.
Publicado: (2020)

The Relationship between Type 1 Diabetes Mellitus, TNF-α, and IL-10 Gene Expression
por: dos Santos Haber, Jesselina Francisco, et al.
Publicado: (2023)

Organokines, Sarcopenia, and Metabolic Repercussions: The Vicious Cycle and the Interplay with Exercise
por: Minniti, Giulia, et al.
Publicado: (2022)

Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
por: de Oliveira dos Santos, Ana Rita, et al.
Publicado: (2021)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
por: Lee, Jin Ha, et al.
Publicado: (2020)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulated Diseases: An Evidence-Based Comprehensive Review
por: Laurindo, Lucas Fornari, et al.
Publicado: (2023)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
por: Losekann, Alexandre, et al.
Publicado: (2015)

Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
por: Min-DeBartolo, Jessica, et al.
Publicado: (2019)

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
por: Sekhon, Anupamjeet Kaur, et al.
Publicado: (2021)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

The effect of synbiotics Bifidobacterium infantis and milk oligosaccharides on shaping gut microbiota community structure and NASH treatment
por: Jena, Prasant Kumar, et al.
Publicado: (2018)

Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice
por: Majeed, Muhammed, et al.
Publicado: (2020)

Pomegranate (Punica granatum L.) and Metabolic Syndrome Risk Factors and Outcomes: A Systematic Review of Clinical Studies
por: Laurindo, Lucas Fornari, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Longitudinal analysis of a dietary mouse model of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
por: Saenz, Marissa, et al.
Publicado: (2023)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
por: Kan Changez, Mah I, et al.
Publicado: (2023)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)()
por: Jha, Pooja, et al.
Publicado: (2014)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
por: Connolly, James J., et al.
Publicado: (2018)

A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Anti-Inflammatory, Antioxidant, and Other Health Effects of Dragon Fruit and Potential Delivery Systems for Its Bioactive Compounds
por: Nishikito, Daniela Franceschi, et al.
Publicado: (2023)

Prevalence of Non Alcoholic Steatohepatitis (NASH) and association with body mass index in obese adolescents in Padang
por: Farlina, Lita, et al.
Publicado: (2013)

Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ekq7isnv7n6i3d9g06ur2oapll